Financials

Discussions Technicals Seasonals

6492 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Senhwa Biosciences, Inc. engages in the research and development of anticancer drug and active pharmaceutical ingredient. It has two agents in clinical development for cancer, which includes CX-5461, a compound that activates p53 and kills cancer cells; and CX-4945, a compound that controls the growth and proliferation of cancer cells. The company was founded by Tai Sen Soong on November 16, 2012 and is headquartered in New Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

6492 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company